Results 141 to 150 of about 35,846 (211)

Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial. [PDF]

Diabetes Obes Metab
Cho YK, Cho JH, Hong SM, Park JH, Lee BW, Yoo JH, Kim JH, Chun SW, Hwang YC, Song KH, Lee WJ.   +10 more
europepmc   +1 more source

Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort study. [PDF]

EClinicalMedicine
Meng LC, Chuang HM, Lai HY, Chen HM, Yang KY, Chen LK, Hsiao FY.   +6 more
europepmc   +1 more source

Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus.

J Clin Endocrinol Metab
Feng Y, Shang B, Yang Y, Zhang D, Liu C, Qin Z, Zhou Y, Meng J, Liu X.   +8 more
europepmc   +1 more source

Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study. [PDF]

Invest Ophthalmol Vis Sci
Pan SY, Weng CH, Tsai SF, Lin HJ, Lin JF, Lin CH, Wang IJ, Chou CC.   +7 more
europepmc   +1 more source

Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Pirera E, Di Raimondo D, D'Anna L, Tuttolomondo A.   +3 more
europepmc   +1 more source

Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention. [PDF]

Cancers (Basel)
Laeeq T, Ahmed M, Sattar H, Zeeshan MH, Ali MB.   +4 more
europepmc   +1 more source

Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study. [PDF]

Clin Med Insights Endocrinol Diabetes
Reghunath SR, Chackochan A, Thunga G, Acharya DU, Shivashankara KN, Ravindra Prabhu A, Acharya LD.   +6 more
europepmc   +1 more source

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis. [PDF]

BMC Cardiovasc Disord
Liang X, Dai J, Wang F.
europepmc   +1 more source

Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study. [PDF]

Front Pharmacol
Kim H, Seo JH, Nam JH, Lim Y, Choi KH, Kim K.   +5 more
europepmc   +1 more source